0.7400 -0.01 (-1.12%)
After hours: 5:02PM EST
|Bid||0.0000 x 3000|
|Ask||0.0000 x 1000|
|Day's Range||0.7289 - 0.8000|
|52 Week Range||0.3240 - 1.6000|
|Beta (3Y Monthly)||2.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
CORAL GABLES, FL / ACCESSWIRE / November 13, 2018 / The U.S. patient engagement solutions market size is anticipated to reach $12.3 billion by 2025, expanding at a CAGR of 19.5% over the forecast period according to reports from Research And Markets*. With the volatility in today's market, many investors have turned to biotechnology and healthcare stocks as a safe haven from the broader market activity. Furthermore, the new age of technology and aging population unable to frequently visit a physical doctor's office has created a larger demand for technology intervention within the healthcare industry.
The Smart Medical Devices Market, for example, is expected to witness healthy growth (no pun intended) according to a report by Market Research Future*. Biotech companies have found that this demand is unwavering and are working toward catering to it by increasing investments toward the development of more efficient methods of self-administration of drugs and diagnosis. Sector trends in healthcare technology and new treatments for rare diseases have sparked more interest in sector stocks.
– Key focus on advancing the development of MAT9001, a proprietary, potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar.
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 10,058,521 entitled, “Omega-3 pentaenoic acid compositions and methods of use” to the Company. The issued patent provides additional intellectual property protection for MAT9001, Matinas’ proprietary prescription-only omega-3 fatty acid-based composition under development for the treatment of cardiovascular and metabolic conditions, through 2033. The issued patent claims cover the Company’s proprietary methods relating to reducing triglyceride levels, total cholesterol, VLDL-cholesterol or apolipoprotein C-III by administering a pharmaceutical composition comprising omega-3 fatty acids comprising eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA).
Dr. Mannino will give an oral presentation titled, “Enabling the Intracellular Delivery of Life-Changing Medicines,” as part of the conference’s Drug Delivery Technology Presentations Session: Non-Injectable Technologies: Oral, discussing controlled release, modified-release, colon-targeted, and orally-disintegrating delivery systems, as well as bioavailability & solubility enhancing technologies. As part of his presentation, Dr. Mannino will discuss the Company’s differentiated lipid nano-crystal (LNC) platform technology which offers an intracellular drug delivery solution with potential advantages for a range of therapeutics, including demonstrated use with small molecules, nucleic acid polymers, proteins, peptides, and vaccines, as well as the potential for efficient and non-immunogenic delivery of gene editing technologies.
- Dr. Matkovits is an industry leader with 20+ years of proven global drug development success bringing 4 approved medicines to several global markets - - Frank Calamusa, CSCP,.
BEDMINSTER, N.J., Sept. 25, 2018 -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular.
Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today announced the appointment of Patrick G. LePore as Vice Chairman to the Company’s Board of Directors. “We are delighted to welcome Pat to the Matinas Board,” commented Herbert Conrad, Chairman of the Matinas BioPharma Board of Directors.
As part of his presentation, Mr. Jabbour will provide a corporate update and will discuss the Company’s differentiated LNC drug delivery platform which offers an intracellular drug delivery solution with potential advantages for a range of therapeutics, including small molecules, nucleic acid polymers, proteins, peptides, vaccines, as well as the targeted delivery of gene editing technologies. Additionally, Mr. Jabbour will provide an overview of the Company's lead and platform-validating product candidate, MAT2203, which utilizes its proprietary LNC formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017 and a positive face-to-face interaction with the FDA in 2018, Matinas has designed a streamlined and risk-mitigated development program focused on a potential pivotal Phase 2 trial of MAT2203 for the prevention of IFIs in patients with acute lymphoblastic leukemia.
LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on NEPT sign up now at www.wallstequities.com/registration. Under evaluation this morning are the following equities: Magenta Therapeutics Inc. (MGTA), Matinas BioPharma Holdings Inc. (NYSE AMER: MTNB), MyoKardia Inc. (NASDAQ: MYOK), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT).
Matinas BioPharma Holdings Inc’s (AMEX:MTNB): Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing antifungal and anti-bacterial therapeutics for the treatment of various infections in theRead More...
NEW YORK, NY / ACCESSWIRE / March 19, 2018 / Matinas BioPharma Holdings, Inc. (NYSE American: MTNB ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 19, 2018, at ...